Abiopharma

🔍 Schwartz Todd G. (Executive)

Company: OppFi Inc. (OPFI)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Acquired 60,000 shares of Class A Common Stock at $7.0498 per share (Direct)
  Date: 2026-08-12 | Code: P | equity_swap_involved: false | shares_owned_after: 493,733.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-12 | Code: H | shares_owned_after: 301,710.00
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-12 | Code: H | nature_of_ownership: By TGS Capital Group, LP | shares_owned_after: 24,656,083.00 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-12 | Code: H | nature_of_ownership: By TGS MCS Capital Group LP | shares_owned_after: 1,949,309.00 | Footnotes: F4

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions with prices ranging from $6.90 to $7.17 for a weighted average purchase price of $7.0498. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F2: The reporting person is the sole trustee of TGS Revocable Trust.
• F3: The reporting person is the manager of the general partner of TGS Capital Group, LP and may be deemed to beneficially own the securities held by TGS Capital Group, LP. The reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
• F4: The reporting person is the manager of the general partner of TGS MCS Capital Group LP and may be deemed to beneficially own the securities held by TGS MCS Capital Group LP. The reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.